Aptose Biosciences Inc. Annual report [Section 13 and 15(d), not S-K Item 405]

Annual report [Section 13 and 15(d), not S-K Item 405]

Note 13 - Share Capital (Details Textual)

Note 13 - Share Capital (Details Textual) - USD ($)								5 Months Ended	11 Months Ended	12 Months Ended		18 Months Ended
Note 13 - Share Capital (Details Textual) - USD ($)	Feb. 12, 2025	Feb. 07, 2025	Nov. 25, 2024	Sep. 11, 2024	Jun. 03, 2024	Jan. 30, 2024	May 25, 2023	May 30, 2024	Apr. 30, 2024	Dec. 31, 2025	Dec. 31, 2024	May 30, 2024	Feb. 03, 2025	Sep. 05, 2024	Jun. 18, 2024	Apr. 01, 2024	Dec. 09, 2022
Hanmi Pharmaceuticals Co Ltd [Member]
Class of Stock [Line Items]
Warrants to purchase common shares, number of warrants										77,972
Change in fair value of warrants															$ 700,000
Shares Issued, Price Per Share (in dollars per share)										$ 51.3
2023 Committed Equity Facility [Member]
Class of Stock [Line Items]
Stock issuance program authorized shares							838
2023 Committed Equity Facility [Member] \| Keystone [Member]
Class of Stock [Line Items]
Financing costs including underwriting costs, professional fees and recognition of deferred financing costs									$ 200,000
Stock Issuance Program, Authorized Amount							$ 25,000,000
Percentage of common shares outstanding.							19.99%									19.99%
Common shares issued (in shares)									41,019		17,003
Cash proceeds from issuing shares											$ 23,000,000
Shares Issued, Price Per Share (in dollars per share)									$ 68.1		$ 40.8
Issuance of common shares under the ESPP share purchase									$ 2,800,000		$ 700,000
2023 Committed Equity Facility [Member] \| Commitment Shares [Member] \| Keystone [Member]
Class of Stock [Line Items]
Common shares issued (in shares)									838		329
2023 Committed Equity Facility [Member] \| Initial Commitment Shares [Member]
Class of Stock [Line Items]
Common shares issued (in shares)							251
Stock Issuance, Percent of Cash Commission to Broker							30.00%
2023 Committed Equity Facility [Member] \| First Back-End Commitment Shares [Member]
Class of Stock [Line Items]
Common shares issued (in shares)							251
Stock Issuance, Percent of Cash Commission to Broker							30.00%
2025 Committed Equity Facility [Member]
Class of Stock [Line Items]
Percentage of common shares outstanding.		19.99%
2025 Committed Equity Facility [Member] \| Maximum [Member]
Class of Stock [Line Items]
Stock Issuance Program, Authorized Amount		$ 25,000,000
Amount agreed to pay for reasonable expenses under purchase agreement		$ 25,000,000
2025 Committed Equity Facility [Member] \| Commitment Shares [Member]
Class of Stock [Line Items]
Stock issuance program authorized shares		8,020
Common shares issued (in shares)		0
The 2025 ATM Offering [Member]
Class of Stock [Line Items]
Stock Issuance Program, Authorized Amount													$ 1,000,000
Common shares issued (in shares)	137,000
Shares Issued, Price Per Share (in dollars per share)	$ 7.31
Proceeds from Issuance of Common Stock, Gross	$ 1,000,000
Issuance of common shares under the ESPP share purchase	$ 800,000
Stock Issuance, Percent of Cash Commission to Broker													3.00%
November 2024 Public Offering [Member]
Class of Stock [Line Items]
Warrants to purchase common shares, exchange price			$ 6
Warrants, Remaining contractual life			5 years
Transaction cost including placement agent fees and professional fees			$ 1,100,000
Placement agent fees			600,000
Professional fees			$ 500,000
Number of shares sold			1,333,333
Sale of stock price per share			$ 6
Proceeds from Issuance of Common Stock, Gross			$ 8,000,000
November 2024 Public Offering [Member] \| Alliance Global Partners [Member]
Class of Stock [Line Items]
Warrants to purchase common shares, exchange price			$ 8.25
Warrants, Remaining contractual life			5 years
Warrants issued			53,333
November 2024 Public Offering [Member] \| Maximum [Member]
Class of Stock [Line Items]
Warrants to purchase common shares, number of warrants			666,599
Private Placement [Member]
Class of Stock [Line Items]
Proceeds from Issuance of Common Stock, Gross						$ 4,000,000
Private Placement [Member] \| Series A Warrants [Member]
Class of Stock [Line Items]
Warrants to purchase common shares, exchange price					$ 34.5
Warrants, Remaining contractual life					5 years
Private Placement [Member] \| Series B Warrants [Member]
Class of Stock [Line Items]
Warrants to purchase common shares, exchange price					$ 34.5
Warrants, maturity date					Mar. 05, 2026
Private Placement [Member] \| Hanmi Pharmaceuticals Co Ltd [Member]
Class of Stock [Line Items]
Warrants to purchase common shares, exchange price						$ 51.3
Warrants, maturity date						Jan. 31, 2029
Common shares issued (in shares)						70,175
Shares Issued, Price Per Share (in dollars per share)						$ 57
Cash transaction costs						$ 300,000
Private Placement [Member] \| Hanmi Pharmaceuticals Co Ltd [Member] \| Common Shares [Member]
Class of Stock [Line Items]
Warrants to purchase common shares, number of warrants						77,972
Private Placement [Member] \| Maximum [Member] \| Series A Warrants [Member]
Class of Stock [Line Items]
Warrants to purchase common shares, number of warrants					128,500
Private Placement [Member] \| Maximum [Member] \| Series B Warrants [Member]
Class of Stock [Line Items]
Warrants to purchase common shares, number of warrants					128,500
Registered Direct Offering [Member]
Class of Stock [Line Items]
Number of shares sold					60,000
Shares Issued, Price Per Share (in dollars per share)					$ 34.5
Proceeds from Issuance of Common Stock, Gross					$ 4,400,000
Cash transaction costs					$ 400,000
Registered Direct Offering [Member] \| H.C. Wainwright [Member]
Class of Stock [Line Items]
Warrants to purchase common shares, exchange price					$ 43.13
Warrants, maturity date					Jun. 03, 2029
Warrants issued					6,423
Registered Direct Offering [Member] \| Pre-Funded Warrants [Member]
Class of Stock [Line Items]
Warrants to purchase common shares, exchange price					$ 0.03
Warrants, maturity date					Jun. 25, 2029
Warrants issued					68,500
September 2024 Common Share Issuance [Member]
Class of Stock [Line Items]
Warrants to purchase common shares, exchange price				$ 0.03
Percentage of shares outstanding														20.00%
Pre-Funded warrants exercised				68,500
Cash proceeds				$ 2,000,000
Common shares issued (in shares)				68,500
Public Offering [Member]
Class of Stock [Line Items]
Warrants to purchase common shares, exchange price						$ 51.3
Warrants, maturity date						Jan. 30, 2029
Common shares issued (in shares)						188,304
Proceeds from Issuance of Common Stock, Gross						$ 9,700,000
Cash transaction costs						$ 1,600,000
Public Offering [Member] \| Newbridge Warrants [Member]
Class of Stock [Line Items]
Warrants to purchase common shares, exchange price						$ 64.13
Public Offering [Member] \| Common Shares [Member]
Class of Stock [Line Items]
Warrants to purchase common shares, number of warrants						188,174
Public Offering [Member] \| Common Shares [Member] \| Newbridge Warrants [Member]
Class of Stock [Line Items]
Warrants to purchase common shares, number of warrants						18,084
Public Offering [Member] \| Hanmi Pharmaceuticals Co Ltd [Member]
Class of Stock [Line Items]
Premium share price (as a percent)						11.00%
Over-Allotment Option [Member]
Class of Stock [Line Items]
Shares Issued, Price Per Share (in dollars per share)						$ 51.3
Common shares issued upon exercise of stock options						$ 24,561
The 2022 ATM Offering [Member]
Class of Stock [Line Items]
Stock Issuance Program, Authorized Amount																	$ 50,000,000
Common shares issued (in shares)								2,717
Cash proceeds from issuing shares											$ (21,000)
Shares Issued, Price Per Share (in dollars per share)								$ 36.6				$ 36.6
Proceeds from Issuance of Common Stock, Gross								$ 100,000				$ 2,100,000
Issuance of common shares under the ESPP share purchase								$ 121,000		$ 0	$ (21,000)	$ 2,000,000
Stock Issuance, Percent of Cash Commission to Broker										3.00%
The 2022 ATM Offering [Member] \| Common Shares [Member]
Class of Stock [Line Items]
Common shares issued (in shares)											2,717
Cash proceeds from issuing shares											$ (21,000)